Kreatinooli-O-fosfaatti (esim. Pro-CK)

Löysin juuri netistä mielenkiintoisen kirjoituksen kreatinooli-O-fosfaatista:

"Creatinol-O-Phosphate, in addition to its cardio-protective effects, has been has also been shown to improve muscle development and increase the capacity of a muscle to perform physical activity. In one study, hand-grip strength was improved by Creatinol-O-Phosphate administration and while remaining unaffected in a placebo group (Nicaise J. Creatinol O-phosphate (COP) and muscular performance: a controlled clinical trial. Curr Ther Res Clin Exp. 1975, 17(6):531-4). Moreover, in another study conducted in elderly subjects, it was found that Creatinol-O- Phosphate improved muscular performance as compared to controls (Cavalieri U, Quadri A, Ghirardi F. Effects of creatinol o-phosphate on the muscle function of elderly people. The T! herapeutic Clinic. 1974, 69: 215-223).

Creatinol-o-phosphate was discovered and by a researcher by the name of Shotte in 1928 who observed its structural similarity to creatine. In vivo COP is similar to creatine in some ways and differs in others having unique and very interesting intrinsic properties! COP and creatine phosphate are very close in appearance because both compounds have a creatine and a phosphate group. Well neither does Fergilicious' back side look like Jack Kavorkian's; yet, Fergie's backside has striking similarities to J-Lo's -- no different that Creatinol-O-Phosphate's striking similarities to Creatine Phosphate. And, that is because Creatinol-O-Phosphate is really DeoxyCreatine-O-Phosphate meaning structurally there is only one Oxide atom difference between COP and Creatine Phosphate and, therefore, can be oxidized into creatine.

COP, aka N-Methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate) has proved to possess anti-ischemic (i.e. keep oxygen levels healthy) and anti-arrhythmic (keeps heart beating with more rhythm) activities associated with improved ionic balance and heart performance. These activities are more evident in pharmacological and clinical conditions involving a hypoxic damage of the heart muscle. When injected i.m., pharmacokinetic studies have shown that absorption of COP to be complete. COP is distributed in all organs, and in particular, in the kidney, liver and heart muscle. The results of the toxicological studies confirm that COP has no side effects and seems to be well-tolerated.(1) In fact, the action of creatinol-O-phosphate on the recovery of heart muscle contraction ability after ischemia (i.e. loss of oxygen) has been shown; thus, creatinol-O-phosphate could exert its cardioprotective effect by an action on anaerobic glycolysis according to one report.(2) As far as the safety of it in humans, the acute clinical tolerance to COP was investigated in volunteer human subjects without heart or renal disease and without other serious illness. COP was administered i.v. at three different dosages, 1020 mg (group A), 2040 mg (group B) and 3060 mg (group C), in comparison with a placebo (group D). Arterial pressure, heart rate, ECG pattern and a complete blood analysis showed no change at any COP dosage, with the exception of blood phosphate, which increased in groups B and C. Cumulative urinary excretion of phosphate and creatinine and diuresis increased (i.e. they urinated more), whereas other urine parameters did not change. Therefore, COP proved to be a very well tolerated drug without any evident side effect.(3) Other studies have that COP improved rhythm disturbances, chest pains and symptoms of contractility failure.(4) COP is an intercellular buffer (a characteristic similar to that of beta-alanine) and increases anaerobic glycolysis allowing you to train longer, harder (past typical sticking and failure points) and improving eccentric contraction - the negative movement in resistance training proven to be the most effective for building muscle!

References:

Marzo A, Ghirardi P. Pharmacological and toxicological properties of creatinol O-phosphate. A review. Arzneimittelforschung 1979;29(9a):1449-52.

Godfraind T, Saleh MM. Action of creatinol-O-phosphate on the contractility changes evoked by hypoxia and ischemia in rat isolated heart. Arzneimittelforschung 1984;34(9):968-72.

Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni B. Acute clinical tolerance of creatinol O-phosphate. Arzneimittelforschung 1979;29(9a):1447-9.

Barlattani M, Guglielmi G, Mammarella A. Creatinol O-phosphate therapy in patients with inadequate coronary circulation. Double-blind clinical trial. Arzneimittelforschung 1979;29(9a):1483-5."